MedTrace Logo

Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

NCT06714123 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-05-07

No results posted yet for this study

Summary

This study will investigate whether the senicapoc drug can prevent the scarring from worsening in interstitial lung disease.

Researchers will compare Senicapoc to a placebo (a look-alike substance that contains no drug) to see if Senicapoc works to prevent lung function worsening.

Participants will be asked to take 3 tablets a day for 26 weeks. Within this period, doctors will follow the participants, ask for experience of adverse events, check lung function and organ status, and participants will need to fill out quality-of-life questionnaires. A total of 5 visits are required, at initiation, after4, 13, 26 and 52 weeks. The final visit will occur 52 weeks after initiation and consist of a normal visit in the outpatient clinic where the doctor asks for relevant information regarding the period after end of administration of the study drug.

Conditions

Interventions

DRUG

Senicapoc

administering 30 mg senicapoc a day, in addition to standard of care.

DRUG

Placebo

Tablets similar in size and color

Sponsors & Collaborators

  • Odense Patient Data Explorative Network

    collaborator OTHER

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Ole Hilberg, Proffesor · Sygehus Lillebælt - Vejle

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Denmark
  • Estonia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06714123 on ClinicalTrials.gov